Published in Medical Letter on the CDC and FDA, July 17th, 2005
This marks the first sale of the Episcan I-200 for use in conjunction with photodynamic therapy (PDT) for the treatment of basal cell carcinoma, a type of skin cancer, and Bowen's disease, a common pre-malignant condition of the skin, and opens a new market for Longport. The purchase of the Episcan I-200 by a hospital within the British National Health System also is expected to provide a greater profile for Longport in the U.K.
The purchase is for routine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.